Related Experiment Video
Updated: Aug 14, 2026
Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique
Published on: March 14, 2016
GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing
R Djafarzadeh1, E Noessner, H Engelmann
1Medizinische Poliklinik, Ludwig-Maximilians-University of Munich, Munich, Germany.
Abstract:
The resistance of tumours to immune-mediated lysis has been linked to the biology of matrix metalloproteinases (MMPs), and specifically to the cell surface expression of MMPs by the tumour cell. The endogenous tissue inhibitors of metalloproteinases (TIMPs) exhibit diverse physiological/biological functions including the moderation of tumour growth, metastasis and apoptosis. These biologic activities are mediated in part by the stoichiometry of TIMP/MMP/cell surface protein interactions. A glycosylphosphatidylinositol (GPI) anchor was fused to TIMP-1 to focus defined concentrations of this inhibitory protein on the surface of three renal cell carcinoma (RCC) cell lines (RCC-26, RCC-53 and A498) independently of cell surface protein-protein interactions. Exogenously added TIMP-1-GPI efficiently inserted into the RCC cell membrane and dramatically altered the association of MMPs with the cell surface. TIMP-1-GPI treatment inhibited RCC proliferation and rendered the normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis but did not alter perforin-mediated lysis by cytotoxic effector cells. The increased sensitivity to FAS-mediated apoptosis correlated with an alteration in the balance of pro- and antiapoptotic BCL-2-family proteins. By interfering with the proliferative capacity and inducing sensitivity to immune effector mechanisms GPI-anchored TIMP-1 may represent a more effective version of the TIMP-1 protein for therapeutic strategies.
Insights
GPI-anchored TIMP-1 enhances cancer cell sensitivity to immune responses by altering matrix metalloproteinase interactions. This modified TIMP-1 inhibits tumor growth and induces apoptosis, suggesting therapeutic potential for renal cell carcinoma.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Tumor resistance to immune lysis is linked to matrix metalloproteinases (MMPs) expressed on tumor cells.
- Tissue inhibitors of metalloproteinases (TIMPs) regulate tumor growth, metastasis, and apoptosis through interactions with MMPs and cell surface proteins.
Purpose of the Study:
- To investigate the therapeutic potential of a glycosylphosphatidylinositol (GPI)-anchored TIMP-1 (TIMP-1-GPI) in renal cell carcinoma (RCC).
- To determine if TIMP-1-GPI can alter MMP association with the cell surface and influence tumor cell sensitivity to immune-mediated apoptosis.
Main Methods:
- TIMP-1 was fused to a GPI anchor to create TIMP-1-GPI.
- TIMP-1-GPI was introduced to three human renal cell carcinoma (RCC) cell lines (RCC-26, RCC-53, A498).
- The effects of TIMP-1-GPI on MMP cell surface association, RCC proliferation, FAS-induced apoptosis, and perforin-mediated lysis were analyzed.
Main Results:
- Exogenous TIMP-1-GPI efficiently inserted into RCC cell membranes, altering MMP cell surface association.
- TIMP-1-GPI treatment inhibited RCC proliferation and increased sensitivity to FAS-induced apoptosis.
- TIMP-1-GPI did not affect perforin-mediated lysis by cytotoxic effector cells.
- Increased FAS sensitivity correlated with altered BCL-2 family protein balance.
Conclusions:
- GPI-anchored TIMP-1 effectively targets tumor cells and modulates MMP interactions.
- TIMP-1-GPI demonstrates potential as a therapeutic agent by inhibiting proliferation and enhancing immune effector mechanisms in renal cell carcinoma.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
